ArriVent BioPharma (AVBP) Current Assets (2023 - 2026)
ArriVent BioPharma (AVBP) posted Current Assets of $348.7 million for Q1 2026, up 4.75% sequentially from $332.9 million in Q4 2025, and up 87.69% YoY from $185.8 million in Q1 2025.
ArriVent BioPharma (AVBP) Current Assets (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Current Assets for 4 years, with the latest figure at $348.7 million in Q1 2026.
- Quarterly Current Assets rose 87.69% year-over-year to $348.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $348.7 million (up 87.69% YoY) and the FY2025 annual result came in at $332.9 million, up 46.66% from the prior year.
- Current Assets improved to $348.7 million in Q1 2026 per AVBP's latest filing, from $332.9 million in the prior quarter.
- Over five years, Current Assets peaked at $348.7 million in Q1 2026 and troughed at $160.0 million in Q4 2023.
- A 4-year average of $275.4 million and a median of $300.5 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2025 and 2026: Current Assets tumbled 43.27% in 2025, then soared 87.69% in 2026.
- Over 4 years, Current Assets stood at $160.0 million in 2023, then jumped by 41.89% to $227.0 million in 2024, then surged by 46.66% to $332.9 million in 2025, then grew by 4.75% to $348.7 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $348.7 million, $332.9 million, and $321.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 394.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 394.17 Mn |
| Mar 31, 2026 | 348.70 Mn |
| Dec 31, 2025 | 332.90 Mn |
| Sep 30, 2025 | 321.22 Mn |
| Jun 30, 2025 | 250.15 Mn |
| Mar 31, 2025 | 185.79 Mn |
| Dec 31, 2024 | 226.98 Mn |
| Sep 30, 2024 | 292.40 Mn |
| Jun 30, 2024 | 308.51 Mn |
| Mar 31, 2024 | 327.48 Mn |
| Dec 31, 2023 | 159.97 Mn |